Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?
Tolvaptan is a highly selective vasopressin receptor 2 antagonist that regulates cyclic adenosine monophosphate levels to inhibit both epithelial cell proliferation and chloride ion excretion, two mechanisms known to induce cyst expansion in autosomal dominant polycystic kidney disease (ADPKD). Tolv...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
Korean Society of Pediatric Nephrology,
2023-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|